Currently, there are 44.21M common shares owned by the public and among those 37.41M shares have been available to trade.
The company’s stock has a 5-day price change of 20.58% and -50.56% over the past three months. HBIO shares are trading -80.79% year to date (YTD), with the 12-month market performance down to -86.92% lower. It has a 12-month low price of $0.28 and touched a high of $3.60 over the same period. HBIO has an average intraday trading volume of 10.90 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 12.89%, -2.21%, and -75.71% respectively.
Institutional ownership of Harvard Bioscience Inc (NASDAQ: HBIO) shares accounts for 58.64% of the company’s 44.21M shares outstanding.
It has a market capitalization of $17.93M and a beta (3y monthly) value of 1.56. The earnings-per-share (ttm) stands at -$1.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 56.52% over the week and 23.02% over the month.
Earnings per share for the fiscal year are expected to increase by 16.67%, and 71.43% over the next financial year.
The Benchmark Company coverage for the Harvard Bioscience Inc (HBIO) stock in a research note released on March 10, 2023 offered a Buy rating with a price target of $4. The Benchmark Company was of a view on January 07, 2021 that the stock is Buy, while Northland Capital gave the stock Outperform rating on December 09, 2020, issuing a price target of $6. KeyBanc Capital Markets on their part issued Overweight rating on November 10, 2020.
